イワモト　タカユキ   Takayuki Iwamoto   岩本　高行    所属   川崎医科大学  医学部 臨床医学　乳腺甲状腺外科学    職種   講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
掲載誌名	正式名：Breast cancer (Tokyo, Japan) 略　 称：Breast Cancer ISSNコード：18804233/13406868
掲載区分	国外
巻・号・頁	27(1),pp.85-91
著者・共著者	Takashi Hojo, Norikazu Masuda, Takayuki Iwamoto, Naoki Niikura, Keisei Anan, Kenjiro Aogi, Tatsuya Ohnishi, Chisako Yamauchi, Masayuki Yoshida, Takayuki Kinoshita, Hideji Masuoka, Yasuaki Sagara, Takashi Sakatani, Yasuyuki Kojima, Hitoshi Tsuda, Hiraku Kumamaru, Hiroaki Miyata, Seigo Nakamura
発行年月	2020/01
概要	BACKGROUND:Adding taxane to an anthracycline-based regimen improves survival in node-positive breast cancer patients, as shown by clinical trials and meta-analyses. However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting.METHODS:Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status. A Cox proportional hazards model was used to evaluate DFS in both groups.RESULTS:There were 4566 eligible patients with ER-positive, HER2-negative breast cancer. During the median follow-up period of 60 months, there were 481 recurrences and 149 deaths. There was no significant difference in DFS between the A + T and A w/o T groups among patients with 1-3 positive nodes, while there was a significant difference among patients with ≥ 4 positive nodes.CONCLUSIONS:In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1-3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases.
DOI	10.1007/s12282-019-00997-w
PMID	31327134